TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Wall Street NYSE Lead
Play
JIM CRAMER

Vaccine vs. Virus: Cramer's 'Mad Money' Recap (Monday 12/14/20)

  • By Scott Rutt
  • Dec 14, 2020 9:22 PM EST
Heart Medication Lead
INVESTING

Amarin Jumps on Heart-Drug Progress in China Trial

  • By Tony Owusu
  • Nov 20, 2020 10:06 AM EST
Early Amarin Vascepa Scripts Are Small, Hard To Interpret
STOCKS

Amarin Loses Appeal in Heart Treatment Patent Case

  • By Rob Lenihan
  • Sep 3, 2020 12:00 PM EDT
Steve Rosenman Says Amarin Has Sticky Web Eyeballs!
INVESTING

Amarin Shares Off - Analysts Mull Prospects of Patent-Case Appeal

  • By Rob Lenihan
  • Sep 2, 2020 3:15 PM EDT
What Is a Ticker Symbol? Definition and Examples
JIM CRAMER

Tale of Two Recoveries: Cramer's 'Mad Money' Recap (Tuesday 8/18/20)

  • By Scott Rutt
  • Aug 18, 2020 8:12 PM EDT
Here Is Why the Bull Market Could Run for Another Decade
JIM CRAMER

Twilight for Index Funds: Cramer's 'Mad Money' Recap (Wednesday 4/15/20)

  • By Scott Rutt
  • Apr 15, 2020 10:57 PM EDT
AstraZeneca Heart Drug Trial No Longer Subject of a Federal Probe
INVESTING

Amarin Shares Crushed After Judge Rules Heart Drug Patents Invalid: Report

  • By Tom Bemis
  • Mar 30, 2020 6:37 PM EDT
Stocks
JIM CRAMER

Rate Cut's No Cure: Cramer's 'Mad Money' Recap (Tuesday 3/3/20)

  • By Scott Rutt
  • Mar 3, 2020 9:01 PM EST
Trader New York Stock Exchange Lead
JIM CRAMER

We Want the Truth: Cramer's 'Mad Money' Recap (Wednesday 1/29/20)

  • By Scott Rutt
  • Jan 29, 2020 8:38 PM EST
bull
JIM CRAMER

Red Flag or Buying Opportunity? Cramer's Mad Money Recap

  • By Scott Rutt
  • Jan 6, 2020 9:15 PM EST
Jim Cramer Picks Twilio as Good Buy Despite Recent Controversy
JIM CRAMER

Invest in Themes: Cramer's 'Mad Money' Recap (Tuesday 12/10/19)

  • By Scott Rutt
  • Dec 10, 2019 8:48 PM EST
Ford Motor, PG&E, Amarin: 'Mad Money' Lightning Round
JIM CRAMER

Ford Motor, PG&E, Amarin: 'Mad Money' Lightning Round

  • By Scott Rutt
  • Nov 19, 2019 8:40 PM EST
Indispensable Tech: Cramer's 'Mad Money' Recap (Tuesday 11/19/19)
JIM CRAMER

Indispensable Tech: Cramer's 'Mad Money' Recap

  • By Scott Rutt
  • Nov 19, 2019 8:36 PM EST
Don't Turn Your Back on This Market: Cramer's 'Mad Money' Recap (Monday 3/19/18)
JIM CRAMER

Are You Confused Yet?: Cramer's 'Mad Money' Recap

  • By Scott Rutt
  • Oct 23, 2019 8:51 PM EDT
Exact Sciences, Wisconsin Energy, Snap: 'Mad Money' Lightning Round
JIM CRAMER

Exact Sciences, Wisconsin Energy, Snap: 'Mad Money' Lightning Round

  • By Scott Rutt
  • Oct 23, 2019 8:27 PM EDT
Global Stocks Slip Despite Wall Street Records; European Tech Gains, Autos Drift
JIM CRAMER

Stocks Handcuffed to Bonds: Cramer's 'Mad Money' Recap

  • By Scott Rutt
  • Aug 14, 2019 8:39 PM EDT
SolarEdge, Amarin, STMicroelectronics: 'Mad Money' Lightning Round
JIM CRAMER

SolarEdge, Amarin, STMicroelectronics: 'Mad Money' Lightning Round

  • By Scott Rutt
  • Aug 14, 2019 8:32 PM EDT
Wild Wall Street, Pot Stock Aphria, Sears' Final Hours? - 5 Things You Must Know
INVESTING

Amarin Shares Show Heart as Biotech Bucks Market Rout

  • By Scott Van Voorhis
  • Aug 14, 2019 3:31 PM EDT
Amarin Dives on Surprise FDA Heart-Drug Review
STOCKS

Amarin Dives on Surprise FDA Heart-Drug Review

  • By M. Corey Goldman
  • Aug 9, 2019 10:49 AM EDT
Fed Should Take the Third Way: Cramer's 'Mad Money' Recap (Tuesday 12/18/18)
JIM CRAMER

Follow These Leaders: Cramer's 'Mad Money' Recap

  • By Scott Rutt
  • Jul 31, 2019 8:25 PM EDT
Roku's Growth Ahead of Where Netflix Was at Same Point, Says William Blair
JIM CRAMER

Roku, Colgate-Palmolive, Amarin: 'Mad Money' Lightning Round

  • By Scott Rutt
  • Jul 31, 2019 8:14 PM EDT
China Tariffs, Uber IPO, Viacom, Symantec and Wynn - 5 Things You Must Know
JIM CRAMER

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap

  • By Scott Rutt
  • Jul 10, 2019 8:56 PM EDT
Planet Fitness: Cramer's Top Takeaways
JIM CRAMER

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

  • By Scott Rutt
  • Jul 10, 2019 8:40 PM EDT
Dow Ends Up 250; Stocks Close Higher on Trade-Talk Hopes
MARKETS

S&P Logs Record Close as Markets Shrug Off U.S.-EU Trade Dispute Worries

  • By Rob Lenihan
  • Jul 2, 2019 4:25 PM EDT
Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says
INVESTING

Amarin Surges on Revenue Guidance Boost

  • By M. Corey Goldman
  • Jul 2, 2019 9:40 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.